Manufacturing & Packaging

Manufacturers should leverage the knowledge base of personnel working in sterility assurance and in microbiology laboratories.

Review article explores the latest developments surrounding expression and purification strategies.

In the midst of being approved for commercial manufacturing of Pluvict, the 70,000 square-foot site was built specifically to accommodate RLT production.

Provider’s Pithampur facility is recognized for its use of Industry 4.0 technology.

Popular works in the category explore 340B guidelines, ‘smart pharma’ capabilities, and commercialization trends.

The most popular pieces pertaining to the supply chain featured ADMs, vaccine supply chains, and wholesalers.

Study analyzes and predicts how conditions in research and development can be predicted via computer simulation.

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

The CDMO’s GMP plant will dedicate 2,500 square feet to the storage of finished products.

Parties will provide processing and packaging machinery services.

Blue Fin Group exec speaks on his upcoming feature.

SVP and Managing Director for Blue Fin Group offers a synopsis of the conference opener.

Berkeley Research Group executive speaks about the role of manufacturers in 340B pricing.

R&D teams need to accelerate how they conduct their research, get to a material, and get to market.

Determination will affect future vaccine cost and accessibility, including in developing countries.

MarketsandMarkets report points to growth of over $3 billion over the next five years.

How setting action-based goals and cultivating partnerships will help overcome challenges associated with implementing a sustainable GHG strategy.

Parties will establish a Center of Excellence in CMIC’s NJ plant.

Northern Ireland hub undergoes $85 million expansion.

CDMO predicts that its facilities can now potentially produce over $400 million in annual revenue.

CDMO’s goal is to increase building’s aseptic manufacturing capacity.

CDMO will financially commit $10.6 million toward semi-solid and non-sterile liquid production.

CDMO’s Heidelberg facility will house the newly-completed manufacturing line.

The report also references a CAGR of 7.8% through that year.

Packaging manufacturers partner up in effort to help tackle pharma’s demand for recyclable packaging.